Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

905
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
905
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

1.3K
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
1.3K
Irritable Bowel Syndrome III: Medical and Nursing Management01:30

Irritable Bowel Syndrome III: Medical and Nursing Management

1.0K
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
1.0K
Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care01:30

Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care

405
A healthcare provider can diagnose a urinary tract infection (UTI) through several methods:Medical History and Symptoms: The provider will take a detailed medical history and ask about symptoms such as frequent urination, burning sensation during urination, and lower abdominal pain.Urinalysis: A clean-catch urine sample is collected in a sterile container and tested for the presence of bacteria, white blood cells (leukocytes), nitrites, blood, and protein. The presence of leukocytes and...
405
Urinary Tract Infection IV: Nursing Management01:17

Urinary Tract Infection IV: Nursing Management

604
In managing urinary tract infections (UTIs) in nursing, a comprehensive assessment is essential. Begin by gathering subjective data, such as the patient’s complaints of dysuria (painful urination), urinary frequency, urgency, suprapubic pain, and any lower abdominal discomfort. This information can be complemented by questions regarding previous UTIs, sexual activity, and personal hygiene practices, which can provide insight into risk factors. Objective assessment should focus on signs...
604
Drugs Affecting GI Tract Motility: Bulk-Forming and Stimulant Laxatives01:22

Drugs Affecting GI Tract Motility: Bulk-Forming and Stimulant Laxatives

836
Laxatives enhance bowel movements and alleviate constipation. They augment the stool's bulk, stimulate intestinal muscle contractions, draw water into the intestines, or soften the stool. There are five key types of laxatives: bulk laxatives, stimulant laxatives, osmotic laxatives, stool softeners, and lubricant laxatives.
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This...
836

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Response to "Comment on 'Symptom Relief and Practice Setting Variation in Bulkamid Injections for Stress Urinary Incontinence'".

Neurourology and urodynamics·2026
Same author

Bulkamid for Recurrent SUI After Suburethral Sling Revision: Single-Center Study.

Urogynecology (Philadelphia, Pa.)·2026
Same author

Frailty, Bone Health, and Radiographic Predictors of Complications After Long-Segment Fusion for Adult Spinal Deformity.

World neurosurgery·2026
Same author

Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA Guideline (2026) Part III: Procedural/Surgical Management.

The Journal of urology·2026
Same author

Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA Guideline (2026) Part II: Medical Management.

The Journal of urology·2026
Same author

Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA Guideline (2026) Part I: Presentation and Evaluation.

The Journal of urology·2026
Same journal

Tips and Tricks for Preventing and Managing Urinary Stoma Complications in the Neurogenic Bladder Population.

Neurourology and urodynamics·2026
Same journal

Reply to the Letter to the Editor Regarding "Age and Nocturnal Polyuria in Nocturia: A Multicenter Voiding Diary Cohort Study".

Neurourology and urodynamics·2026
Same journal

Letter to the Editor on "A Novel Template for Intravesical Botulinum Toxin Injection in Patients With Idiopathic Overactive Bladder: A Cohort Study".

Neurourology and urodynamics·2026
Same journal

Treatment Dropout in Pediatric Enuresis: A Retrospective Cohort Study at a Tertiary Children's Hospital.

Neurourology and urodynamics·2026
Same journal

Neurourologic Outcomes in Men With Obstructive Sleep Apnea.

Neurourology and urodynamics·2026
Same journal

Engineering Advances in Neurogenic Lower Urinary Tract Dysfunction (NLUTD): Current State and Future Directions - A Report From the Neurogenic Bladder Research Group (NBRG).

Neurourology and urodynamics·2026
See all related articles

Related Experiment Video

Updated: Apr 10, 2026

Breathing-controlled Electrical Stimulation BreEStim for Management of Neuropathic Pain and Spasticity
11:34

Breathing-controlled Electrical Stimulation BreEStim for Management of Neuropathic Pain and Spasticity

Published on: January 10, 2013

23.8K

Symptom Relief and Practice Setting Variation in Bulkamid Injections for Stress Urinary Incontinence.

Christina Sze1, Dhillon Advano2, Carolina Martinez Fernandez2

  • 1Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.

Neurourology and Urodynamics
|April 9, 2026
PubMed
Summary
This summary is machine-generated.

Bulkamid™ injection effectively treats stress and mixed urinary incontinence, improving quality of life. Procedures without anesthesia may require repeat injections, while younger patients might need sling surgery later.

More Related Videos

Urinary Bladder Distention Evoked Visceromotor Responses as a Model for Bladder Pain in Mice
11:46

Urinary Bladder Distention Evoked Visceromotor Responses as a Model for Bladder Pain in Mice

Published on: April 27, 2014

18.5K
Evaluation of Biomaterials for Bladder Augmentation using Cystometric Analyses in Various Rodent Models
10:19

Evaluation of Biomaterials for Bladder Augmentation using Cystometric Analyses in Various Rodent Models

Published on: August 9, 2012

20.0K

Related Experiment Videos

Last Updated: Apr 10, 2026

Breathing-controlled Electrical Stimulation BreEStim for Management of Neuropathic Pain and Spasticity
11:34

Breathing-controlled Electrical Stimulation BreEStim for Management of Neuropathic Pain and Spasticity

Published on: January 10, 2013

23.8K
Urinary Bladder Distention Evoked Visceromotor Responses as a Model for Bladder Pain in Mice
11:46

Urinary Bladder Distention Evoked Visceromotor Responses as a Model for Bladder Pain in Mice

Published on: April 27, 2014

18.5K
Evaluation of Biomaterials for Bladder Augmentation using Cystometric Analyses in Various Rodent Models
10:19

Evaluation of Biomaterials for Bladder Augmentation using Cystometric Analyses in Various Rodent Models

Published on: August 9, 2012

20.0K

Area of Science:

  • Urology
  • Minimally Invasive Surgery
  • Female Pelvic Medicine

Background:

  • Bulkamid™ transurethral injection is a minimally invasive option for stress urinary incontinence (SUI) and mixed urinary incontinence (MUI).
  • Predictors for repeat injections, progression to sling surgery, and anesthesia's impact on Bulkamid™ efficacy require further definition.

Purpose of the Study:

  • To evaluate the effectiveness of Bulkamid™ injection for SUI/MUI.
  • To identify predictors for repeat Bulkamid™ injections and progression to sling surgery.
  • To assess the influence of anesthesia type on Bulkamid™ treatment outcomes.

Main Methods:

  • Retrospective review of 284 women undergoing Bulkamid™ injection for SUI/MUI.
  • Collection of baseline demographics, comorbidities, and symptom scores.
  • Statistical analysis including paired Wilcoxon signed-rank tests and univariate logistic regression to identify predictors and compare outcomes by anesthesia use.

Main Results:

  • Bulkamid™ significantly improved continence and quality-of-life measures, with decreased pad use and UDI-6 scores.
  • 16.5% of patients required repeat injection, predicted by procedures performed without general/sedative anesthesia (OR 2.82).
  • 6.0% progressed to sling surgery, with younger age as a predictor (OR 0.95 per year).

Conclusions:

  • Bulkamid™ injection is a safe and effective minimally invasive treatment for SUI/MUI, offering significant symptom relief.
  • Anesthesia choice impacts the likelihood of repeat injections, with non-anesthetized procedures associated with higher rates.
  • Bulkamid™ is a valuable alternative to sling surgery, particularly for women seeking less invasive options.